NuVision is managed by an expert team of directors encompassing essential skills of business development, clinical ophthalmic surgery, medical affairs, GMP manufacturing and research and development. Together we create a unique dynamic that will enable the company to grow and evolve to redefine sight saving biotherapies.
Dr Mark Treherne
Mark Treherne joined the NuVision team in 2018 as Chairman of the company. Mark has a PhD in Pharmacology from Cambridge University along with over 25 years of industrial R&D experience in the discovery and development of novel treatments for diseases with unmet medical need. Mark is also currently Chairman of Talisman Therapeutics and Chief Executive of Avilex Pharma.
Prior to this, Mark has carried out research work with Pfizer and in 1997 set up Cambridge Drug Discovery (CDD) as Chief Executive which was sold to BioFocus in 2001.
Mark was formerly Chairman of ERBI for 3 years, which represents the biotechnology companies in the East of England (now One Nucleus). He was also Chief Executive of the Life Sciences Organisation of UK Trade & Investment until 2016. Mark is an author of over 70 articles published in the scientific and trade press.
Andrew Hopkinson, PhD, is the Chief Executive Officer, founder and visionary of NuVision. Andrew has 15 years’ translational research expertise in ophthalmic regenerative medicine as the Principal Research Fellow at Nottingham Centre For Eye research, which is part of Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham.
During his time at the University he and his multidisciplinary research team have been engaged in developing innovative technologies to repair and regenerate the injured ocular surface for visual rehabilitation. His research pioneered the development of Tereo processing and Omnigen. He continues to drive ground breaking research discoveries from the bench to pre-clinical and clinical realisation, to create an exciting future portfolio of innovative Biotherapies for NuVision.
During his academic career, Dr Hopkinson has published over 50 scientific papers in leading journals in the fields of ophthalmology and tissue engineering, and has filed 4 patents.
Dr Andrew Hopkinson
Mr Peter Dines
As a highly successful entrepreneur and investor, Peter heads up Life Science Investments at Mercia Fund Management.
He has over 20 years’ experience in the healthcare sector, where during this period, Peter founded Surgi C Group which he grew and sold to a private equity backed company. Other key healthcare positions held include Cisiv, Diagnostic World and Spring Active.
Roger Teasdale joined the Board as an Independent Non-Executive Director in 2018. Roger enjoyed a successful 25 year career at Smith & Nephew, the FTSE 100 Medical device business focused on the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of $4.8bn and operations in 120 countries. For his last 5 years at Smith & Nephew, Roger was President of the Global Advanced Wound Management business with sales of $1.4bn and 4000 people in 80 countries. Roger gained a proven international track record in driving revenue and profit growth in the medical device industry. His most recent role is Group Managing Director at Premier Technical Services Group, a listed niche specialist service provider. Roger is a qualified Chartered Accountant and holds a BA in Accounting and Management Control.
Independent Non-Executive Director
Sales & Marketing Director
Jonathan Hamill-Keays joined the NuVision in 2018 as our Sales and Marketing Director. Jonathan has over 30 years experience in clinical research, Sales and Marketing and Business Development. Previous positions include working in Operations at Smith Klein & French, clinical data management at Glaxo Laboratories and Clinical Research Manager at Serono Laboratories prior to completing an MBA at Bradford University. Jonathan joins us from Chiesi Ltd, where he established and grew their Specialist Medicines Division in the UK including the launch of products in Neonatal Intensive Care, Cystic Fibrosis and Transplantation. Jonathan’s extensive knowledge and expertise in driving sales together with management and leadership skills will be hugely beneficial to NuVision as the company expands.
Geert joined NuVision as our HTA Designated Individual & Regulatory Manager in 2019. He was introduced to tissue banking in 2002 while managing one of only two heart valve banks in South-Africa during which he was responsible for ensuring a national supply of quality-controlled cryopreserved human cardiac valves for transplant in South Africa as well as export to Germany. In 2004 he expanded his focus to include a program for the processing of frozen and dehydrated human amniotic membrane-based therapies for ophthalmic use in South Africa, later extending the programme to include the production of umbilical cord blood serum eye drops. Since moving to the UK Geert has continued his focus in tissue banking. In 2017 he joined Moorfield Eye Hospital as the Manager and Designated Individual for the Moorfields Lions Eye Bank.
Geert holds a Master’s Degree in Biological Science from the University of South Africa, a Bachelor’s degree in Veterinary Reproductive Sciences and Molecular Biology from the Tshwane University of Technology and a Diploma in Tissue Banking from the Universitat De Barcelona. He is experienced in ISO 9001 and ISO 13485 Quality Management Systems.
Designated Individual and Regulatory Manager
Adrian Del Arenal Martin
Adrian Del Arenal Martin is a Biotechnology Engineer from the Monterrey Institute of Technology in Mexico. He has pilot plant lab experience with recombinant protein bioprocessing. He also graduated from the University of Nottingham with a MSc. in Biopharmaceutics and Business and has gained start-up business knowledge as a intern SME consultant at BioCity.
Adrian joined the team in 2017 as a Intern Manufacturing Technician, and since summer 2018, he has been appointed as the Operations Manager for the company. He is now the responsible for overseeing procurement, human resources, sales order processing and other general operations areas.
Adriana Oikonomou, PhD, is the Facility & Quality Manager of NuVision. Adriana has over 12 years’ experience of working with Quality Assurance in a clinical setting.She obtained her PhD degree from Imperial College London in 2004 and joined the University of Warwick as a Post-Doctoral Researcher. During this time, she became the Laboratory Manager of her research team facilities and joined the University’s Quality Assurance Committee.In 2006 Adriana joined the NHS as the Operational Manager of a purpose-built, HTA licensed cleanroom facility at the Queen’s Medical Centre, Nottingham University Hospitals NHS Trust. The cleanroom facility was set up to accommodate different clinical groups within NUH Trust working on cutting-edge, translational research, processing/storing human tissues/cells for various therapeutic applications. During her time at NUH NHS Trust, Adriana also worked with the Ophthalmology team, processing frozen amniotic membrane. In 2016, Adriana joined NuVision as a Quality Manager and in turn, this position evolved into Designated Individual from 2017 to early 2019. In 2019, Adriana resumed her post as Facility & Quality Manager; her role is to assist the new Designated Individual regarding regulatory matters, to oversee the laboratory facilities at NuVision and to write and maintain Standard Operating Procedures, to ensure staff has clear and comprehensive protocols to follow, which comply with the necessary quality standards.
Dr Adriana Oikonomou
Facilities and QA Manager
María J. Mendoza is the Process Development Officer at NuVision. Her experience includes molecular, cell biology and immunology research. Graduated from the University of Nottingham with a MSc. in Stem Cell Technology, she has knowledge of regenerative therapies and translational technologies. As an intern in NuVision, Maria has been involved in the translation and implementation of OmnigenTM manufacture into clinical standards. She oversees OmnigenTM manufacture, process development and translation of new research technologies into clinical standards following the HTA requirements.
Dr Emily Britchford is the Research and Development Officer at NuVision. She has several years’ experience in both academic and applied scientific research. Emily has recently graduated with a PhD in Tissue Engineering at the University of Nottingham as part of the EPSRC doctoral training program in regenerative medicine.
Emily has a dual role also working as a post-doctoral research associate in Academic Ophthalmology at the University of Nottingham. Her research interests focus on the development of Omnigen application for acute ocular surface trauma.
Dr Emily Britchford
Research and Development Officer
Veterinary Liaison Officer
Rebecca has a degree in Bioveterinary Science from The University of Liverpool.
She has gained experience in sales, marketing and administration through
She will be product specialist for veterinary customers as well as being
involved in manufacturing Omnigen and maintaining the Tissue Processing Facility.
Our sales team was established in 2018 in order to ensure greater customer services to those already using our product and to also raise awareness throughout the UK, in both the NHS and private hospitals.
Sandra Johnson, Lynn Paine & Julie Munro
Territory Development Managers
Duncan Rawlins, Suki Bal & Joe Brown
Our highly skilled dedicated manufacturing team responsible for creating our flagship product Omnigen.
Interested in purchasing Omnigen?
Register your interest
Have a question about our products or pipelines?
Speak to our team of experts